Explore the latest in ovarian cancer, including recent advances in epidemiology, screening, genetic testing, and management of the disease.
This single-arm, phase 2 nonrandomized clinical trial assesses the efficacy and safety of combined pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide in women with recurrent platinum-sensitive, platinum-resistant, or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer.
This cross-sectional study assesses whether the rate of positive BRCA test results changed between 2008 and 2018 among older women in the United States.
This cohort study compares time trends in the use of neoadjuvant chemotherapy and survival rates among women with advanced-stage epithelial ovarian cancer.
This cohort study assesses whether TP53 clonal variants can be detected in Papanicolaou test samples from women later diagnosed with high-grade serous epithelial ovarian cancer (HGS-EOC).
This case-control study examines the association of polygenic risk scores with changes in breast cancer risk in women who are carriers of pathogenic variants in breast cancer susceptibility genes.
This cohort study examines the association between the use of minimally invasive surgery, capsule rupture, and survival among women with stage I epithelial ovarian cancer.
This pooled analysis analyzes the association between breastfeeding (ie, ever/never, duration, timing) and ovarian cancer risk overall and by histotype.
This secondary analysis of a randomized clinical trial assesses treatment outcomes in women with different biological types of breast cancer according to germline variant status of BRCA1/2 and non-BRCA1/2 breast cancer predisposition genes.
This study uses mendelian randomization to estimate the associations between genetic variants related to reduced HMG-CoA reductase activity and epithelial ovarian cancer in the general population and in BRCA1/2 mutation carriers.
This systematic review and meta-analysis evaluates whether progression-free survival is a validated surrogate end point for overall survival in patients with advanced ovarian cancer.
This cohort study uses pooled data from 4 cohorts to estimate associations between perineal use of body powder and ovarian cancer in US women.
This cohort study uses data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screen Trial to examine the associations among regular aspirin use, obesity, and all-cause and cancer mortality among older adults.
This cost-effectiveness microsimulation modeling study estimates incremental lifetime effects, costs, and cost-effectiveness of multigene testing of all patients with breast cancer compared with selective testing based on family history or clinical criteria.
This phase 2 clinical trial examines the use of nivolumab combined with bevacizumab in treatment of women with relapsed platinum-sensitive or platinum-resistant ovarian cancer.
In this narrative medicine essay, a physiatrist recalls his role in telling his wife of her diagnosis of metastatic ovarian cancer, his support during her inexorable decline, and how the experiences of her passing drew his family closer, nurtured his appreciation for relationships, the wonder of nature, and the renewed sense of connection to the world.
This JAMA Patient Page describes the US Preventive Services Task Force’s recently published recommendations on risk assessment and genetic counseling and testing for BRCA mutations and BRCA-related cancers.
This systematic review to support the 2019 US Preventive Services Task Force Recommendation Statement on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer summarizes published evidence on the benefits and harms of assessment, counseling, and testing in women without recently diagnosed BRCA1/2-related cancer.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: